Inloggad som:
Brightline-1
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Brightline-1
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
PLACEHOLDER
Randomisering mellan studiearm och rutincytostatika till liposarkom.
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2023-03-18)